Prostatic Hyperplasia Treatment and Cancer Prevention

Early Phase 1UnknownNCT03064282

Manchanda Medical Clinic40 enrolled

Overview

Treatment of patients with prostatic hyperplasia with topical papaverine.

Patients with obstructive voiding and high PSA to be studied for the regression of symptoms and declining PSA.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Prostatic Hyperplasia

Interventions

PlaceboOTHER

observation of skin changes if any

papaverineDRUG

observation of symptoms

Eligibility

Sex: MALEMin age: 50 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * patients with symptoms e.g. obstructive voiding, hyperplasia and high PSA Exclusion Criteria: * patients on chemotherapy * abnormal lab values e.g. liver function, GFR and CAD

Outcomes

Primary Outcomes

Laboratory tests to measure regression of symptoms

patients follow-up on regular intervals

Time frame: every 4 weeks up to 16 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.